Merck's (MRK) Suvorexant Helps People Sleep, Says FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Merck's (MRK) Suvorexant Faces Challenges at FDA
May 20, 2013 1:02 PM EDTLeerink Swann today maintained a Market Perform rating on Merck (NYSE: MRK). Recent FDA statements question the safety of sleep aid Suvorexant at higher doses.
Commenting, analyst Seamus Fernandez said, "FDA documents for suvorexant are supportive of the drug's efficacy but... More
